Glaxo in-licenses Eisai’s Paritec in India
EPP News Bureau – Mumbai
GlaxoSmithKline Pharmaceuticals (GSK) has in-licensed Paritec (rabeprazole sodium) from Eisai Pharmaceuticals India to co-promote it in India. Paritec is a proton pump inhibitor discovered and developed by Eisai Co for treating acid-related disorders like peptic ulcers and reflux gastric disorders.
Commenting on the development, S Kalyansundaram, managing director, GSK, said, ‘‘GSK has a strong presence in the gastro-intestinal market and enjoys immense goodwill among the medical fraternity on account of Zantac.’’
The market size in this product segment is estimated at Rs 80 crore out of the anti pepti ulcerant market of Rs 600 crore
Kalyansundaram declined to comment on the pricing of the product or on the revenue it will generate.
The market size in this product segment is estimated at Rs 80 crore out of the anti pepti ulcerant market of Rs 600 crore. Analysts tracking the sector said that there are 40 generic products in the same category currently available in the market.
According to Hideshi Honda, executive officer and vice president (global pharmaceuticals), Eisai Co, said, ‘‘We studied the Indian market and decided to launch Paritec, one of our global blockbusters with worldwide sales of 132 billion yen.’’ This is the second product out-licensed by Eisai to a company in India The first was methycobal tablets and injections to Wockhardt for nerve disorders.